Parexel to be acquired by PE in $5bn deal

By Melissa Fassbender contact

- Last updated on GMT

Parexel has entered an agreement to be acquired by Pamplona Capital Management. (Image: iStock/pichet_w)
Parexel has entered an agreement to be acquired by Pamplona Capital Management. (Image: iStock/pichet_w)

Related tags: Josef von rickenbach, Private equity, Investment

Parexel International Corporation has signed a definite agreement to be acquired by the private equity firm Pamplona Capital Management, LLP.

Under the agreement, announced this morning, Pamplona will acquire all outstanding shares of the contract research organization (CRO) for $88.10 per share in cash.

The transaction, which is valued at approximately $5.0bn, is expected to close early in the fourth quarter of 2017.

Today’s announcement is the culmination of a comprehensive review of the opportunities available to the Company, including interest solicited and received from multiple parties with the assistance of independent financial and legal advisors,​” Josef von Rickenbach, Chairman and CEO of Parexel commented in the release.

Pamplona has previously invested in nThrive, Formativ Health, Brighton Health Group, Alvogen, Spreemo, PatientCo, and Intralign.

The deal comes on the heels of several private equity investments​ in the contract research and manufacturing industry, including the recent purchase of AMRI by The Carlyle Group.

Parexel is not providing any additional comment at this time.

Related news

Show more

Related products

show more

Validating The Simoa Technology

Validating The Simoa Technology

Frontage Laboratories | 01-Oct-2019 | Technical / White Paper

Frontage is the first and only laboratory to validate Quanterix’ Simoa HD1 Analyzer for performing immunoassays. Most of the advanced instruments used...

Related suppliers

Follow us

Products

View more

Webinars